Overview

Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)

Status:
Terminated

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

Metformin is thought to activate AMP-activated protein kinase (AMPK), a major sensor of cellular energy levels and a key enzyme limiting cellular growth during times of cellular stress. Once activated, this enzyme restricts anabolic processes such as protein, cholesterol and fatty acid synthesis and inhibits mTOR, a protein kinase responsible for unregulated growth. MTOR is upregulated in a variety of tumors, including NSCLC providing rationale to take advantage of this pathway with metformin.

Phase:

Phase 2

Details

Lead Sponsor:

Beth Israel Medical Center

Collaborator:

St. Luke's-Roosevelt Hospital Center

Treatments:

Metformin